DK2256135T3 - Proteolytisk spaltbart fusionsprotein, der omfatter en blodkoagulationsfaktor - Google Patents

Proteolytisk spaltbart fusionsprotein, der omfatter en blodkoagulationsfaktor Download PDF

Info

Publication number
DK2256135T3
DK2256135T3 DK10168453.8T DK10168453T DK2256135T3 DK 2256135 T3 DK2256135 T3 DK 2256135T3 DK 10168453 T DK10168453 T DK 10168453T DK 2256135 T3 DK2256135 T3 DK 2256135T3
Authority
DK
Denmark
Prior art keywords
fusion protein
blood coagulation
coagulation factor
proteolytically cleavable
cleavable fusion
Prior art date
Application number
DK10168453.8T
Other languages
English (en)
Inventor
Hubert Metzner
Thomas Weimer
Stefan Schulte
Original Assignee
Csl Behring Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38430551&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2256135(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from EP06012262A external-priority patent/EP1867660A1/en
Application filed by Csl Behring Gmbh filed Critical Csl Behring Gmbh
Application granted granted Critical
Publication of DK2256135T3 publication Critical patent/DK2256135T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K19/00Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745Blood coagulation or fibrinolysis factors
    • C07K14/755Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745Blood coagulation or fibrinolysis factors
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62DNA sequences coding for fusion proteins
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/48Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424Serine endopeptidases (3.4.21)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/48Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6472Cysteine endopeptidases (3.4.22)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/31Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DK10168453.8T 2006-06-14 2007-06-14 Proteolytisk spaltbart fusionsprotein, der omfatter en blodkoagulationsfaktor DK2256135T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP06012262A EP1867660A1 (en) 2006-06-14 2006-06-14 Proteolytically cleavable fusion protein comprising a blood coagulation factor
US81962006P 2006-07-11 2006-07-11
EP07726010.7A EP2032607B2 (en) 2006-06-14 2007-06-14 Proteolytically cleavable fusion protein comprising a blood coagulation factor

Publications (1)

Publication Number Publication Date
DK2256135T3 true DK2256135T3 (da) 2019-06-11

Family

ID=38430551

Family Applications (2)

Application Number Title Priority Date Filing Date
DK21162926.6T DK3896090T3 (da) 2006-06-14 2007-06-14 Proteolytisk spalteligt fusionsprotein omfattende en blodkoagutionsfaktor
DK10168453.8T DK2256135T3 (da) 2006-06-14 2007-06-14 Proteolytisk spaltbart fusionsprotein, der omfatter en blodkoagulationsfaktor

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK21162926.6T DK3896090T3 (da) 2006-06-14 2007-06-14 Proteolytisk spalteligt fusionsprotein omfattende en blodkoagutionsfaktor

Country Status (9)

Country Link
EP (2) EP3896090B1 (da)
JP (1) JP5800458B2 (da)
KR (1) KR101641899B1 (da)
AU (1) AU2007260185B2 (da)
CA (1) CA2655248C (da)
DK (2) DK3896090T3 (da)
ES (2) ES2889920T3 (da)
PL (2) PL2032607T5 (da)
WO (1) WO2007144173A1 (da)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
EP2291523B1 (en) 2008-06-24 2014-12-17 CSL Behring GmbH Factor viii, von willebrand factor or complexes thereof with prolonged in vivo half-life
JP5936112B2 (ja) 2009-02-11 2016-06-15 アルブミディクス アクティーゼルスカブ アルブミン変異体及び複合体
US20120148557A1 (en) * 2009-08-20 2012-06-14 Ulrich Kronthaler Albumin fused coagulation factors for non-intravenous administration in the therapy and prophylactic treatment of bleeding disorders
US20120263701A1 (en) 2009-08-24 2012-10-18 Volker Schellenberger Coagulation factor vii compositions and methods of making and using same
CA2776241A1 (en) 2009-10-30 2011-05-05 Novozymes Biopharma Dk A/S Albumin variants
JP5984676B2 (ja) 2009-12-18 2016-09-06 シーエスエル、リミテッド ポリペプチドを精製する方法
EP2371857A1 (en) * 2010-04-01 2011-10-05 CSL Behring GmbH Factor XII inhibitors for treating interstitial lung disease
UA115120C2 (uk) * 2010-07-09 2017-09-25 Байоджен Хемофіліа Інк. Спосіб застосування химерного поліпептиду фактора ix
KR20140002601A (ko) 2010-07-09 2014-01-08 바이오겐 이데크 헤모필리아 인코포레이티드 키메라 응고 인자
CN103732628B (zh) * 2011-03-03 2017-06-23 酵活有限公司 多价杂多聚体骨架设计和构建体
US9597378B2 (en) * 2011-10-06 2017-03-21 Hanmi Science Co., Ltd. Blood coagulation factor VII and VIIa derivatives, conjugates and complexes comprising the same, and use thereof
EP2780364A2 (en) 2011-11-18 2014-09-24 Eleven Biotherapeutics, Inc. Proteins with improved half-life and other properties
CN104271150A (zh) 2012-01-12 2015-01-07 比奥根艾迪克Ma公司 嵌合因子viii多肽及其用途
PL2814502T3 (pl) 2012-02-15 2018-02-28 Csl Behring Gmbh Warianty czynnika von Willebranda mające ulepszone powinowactwo do wiązania czynnika VIII
EP2822577B1 (en) 2012-02-15 2019-02-06 Bioverativ Therapeutics Inc. Recombinant factor viii proteins
LT2814840T (lt) 2012-02-15 2020-02-25 Bioverativ Therapeutics Inc. Faktoriaus viii kompozicijos ir jų gavimo ir naudojimo būdai
EP3330283A3 (en) 2012-03-16 2018-07-11 Albumedix A/S Albumin variants
PT2882450T (pt) 2012-07-11 2020-02-19 Bioverativ Therapeutics Inc Complexo de fator viii com xten e a proteína fator de von willebrand, e utilizações do mesmo
CN104768571B (zh) 2012-07-13 2018-11-09 酵活有限公司 多价异多聚体支架设计和构建体
WO2014052490A1 (en) 2012-09-25 2014-04-03 Biogen Idec Ma Inc. Methods of using fix polypeptides
EP2917233A1 (en) 2012-11-08 2015-09-16 Novozymes Biopharma DK A/S Albumin variants
WO2014125082A1 (en) 2013-02-16 2014-08-21 Novozymes Biopharma Dk A/S Pharmacokinetic animal model
UY35463A (es) 2013-03-15 2014-10-31 Biogen Idec Inc Formulaciones de polipéptido fc-factor ix.
ES2657291T3 (es) 2013-04-22 2018-03-02 Csl Ltd. Un complejo covalente de factor de von Willebrand y factor VIII asociado por un puente disulfuro
EP3013359A4 (en) * 2013-06-28 2017-01-25 Biogen MA Inc. Thrombin cleavable linker
EP3033097B1 (en) 2013-08-14 2021-03-10 Bioverativ Therapeutics Inc. Factor viii-xten fusions and uses thereof
DK4176894T3 (da) 2014-01-10 2024-05-27 Bioverativ Therapeutics Inc Kimære faktor viii-proteiner og anvendelser deraf
EP3164150B1 (en) 2014-07-02 2020-11-04 CSL Behring Lengnau AG Modified von willebrand factor
EP3298036B1 (en) 2015-05-22 2022-04-06 CSL Behring Lengnau AG Methods for preparing modified von willebrand factor
RU2017145014A (ru) 2015-05-22 2019-06-24 Цсл Беринг Ленгнау Аг Усеченные полипептиды фактора фон виллебранда для лечения гемофилии
AU2016301303B2 (en) 2015-08-03 2021-10-07 Bioverativ Therapeutics Inc. Factor IX fusion proteins and methods of making and using same
WO2017029407A1 (en) 2015-08-20 2017-02-23 Albumedix A/S Albumin variants and conjugates
US20180340208A1 (en) * 2015-10-15 2018-11-29 Woods Hole Oceanographic Institution Compositions and methods for absolute quantification of proteins
RU2018128613A (ru) 2016-01-07 2020-02-07 Цсл Беринг Ленгнау Аг Мутированный фактор фон виллебранда
MX2018008337A (es) 2016-01-07 2018-09-17 CSL Behring Lengnau AG Factor de von willebrand truncado mutado.
TW201828974A (zh) 2016-11-11 2018-08-16 瑞士商Csl貝林重組技能公司 用於血管外施予以治療或預防凝血疾病之截短型類血友病因子(von Willebrand factor)多肽類
EP3538133B1 (en) 2016-11-11 2021-02-17 CSL Behring Lengnau AG Truncated von willebrand factor polypeptides for treating hemophilia
AU2018264581B2 (en) * 2017-05-11 2022-05-19 Zentrum Für Forschungsförderung In Der Pädiatrie Gmbh Concept for the treatment of monogenetic disorders
MX2020003351A (es) 2017-09-27 2020-10-12 Sigilon Therapeutics Inc Metodos, composiciones y elementos implantables que comprenden celulas activas.
US20210145889A1 (en) 2018-04-04 2021-05-20 Sigilon Therapeutics, Inc. Methods, compositions, and implantable elements comprising stem cells
TW202014181A (zh) 2018-04-04 2020-04-16 美商希吉隆醫療公司 可植入顆粒及相關方法
AU2019270184A1 (en) 2018-05-18 2020-11-26 Bioverativ Therapeutics Inc. Methods of treating hemophilia A
UY38389A (es) 2018-09-27 2020-04-30 Sigilon Therapeutics Inc Dispositivos implantables para terapia celular y métodos relacionados
KR20210141608A (ko) 2019-03-19 2021-11-23 체에스엘 베링 렝나우 아게 치료요법에서 인자 ix 변이체 및 이의 용도
CN114072420B (zh) 2019-07-04 2024-06-11 康诺贝林伦瑙有限公司 用于增加凝血因子viii的体外稳定性的截短的血管性血友病因子(vwf)
WO2024081309A1 (en) 2022-10-11 2024-04-18 Sigilon Therapeutics, Inc. Engineered cells and implantable elements for treatment of disease
WO2024081310A1 (en) 2022-10-11 2024-04-18 Sigilon Therapeutics, Inc. Engineered cells and implantable elements for treatment of disease

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GR860984B (en) 1985-04-17 1986-08-18 Zymogenetics Inc Expression of factor vii and ix activities in mammalian cells
GB8927722D0 (en) 1989-12-07 1990-02-07 British Bio Technology Proteins and nucleic acids
WO1996001653A1 (en) * 1994-07-11 1996-01-25 Board Of Regents, The University Of Texas System Methods and compositions for the specific coagulation of vasculature
EP1276756A4 (en) 2000-04-12 2004-06-09 Human Genome Sciences Inc ALBUMIN FUSION PROTEINS
WO2002004598A2 (en) 2000-07-12 2002-01-17 Immunex Corporation Improvement of cell culture performance by inhibitors of pyruvate dehydrogenase kinase
PL374311A1 (en) 2001-12-21 2005-10-03 Immunex Corporation Methods for purifying protein
CA2475388A1 (en) 2002-02-14 2003-08-21 William J. Rutter Chimeric molecules for cleavage in a treated host
AU2003265866A1 (en) * 2002-09-03 2004-03-29 Vit Lauermann Targeted release
EP1444986A1 (en) * 2003-02-07 2004-08-11 Aventis Behring GmbH Pharmaceutical preparation for the improved treatment of blood-clotting disorders
US20050176108A1 (en) 2003-03-13 2005-08-11 Young-Min Kim Physiologically active polypeptide conjugate having prolonged in vivo half-life
TWI353991B (en) * 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
EP1624891B2 (en) 2003-05-06 2013-04-10 Biogen Idec Hemophilia Inc. Clotting factor-fc chimeric proteins to treat hemophilia
CN1871252A (zh) 2003-09-05 2006-11-29 Gtc生物治疗学公司 在转基因哺乳动物奶中生产融合蛋白的方法
EP1816201A1 (en) * 2006-02-06 2007-08-08 CSL Behring GmbH Modified coagulation factor VIIa with extended half-life

Also Published As

Publication number Publication date
EP3896090A1 (en) 2021-10-20
KR20090023486A (ko) 2009-03-04
CA2655248A1 (en) 2007-12-21
ES2910207T3 (es) 2022-05-11
WO2007144173A1 (en) 2007-12-21
JP5800458B2 (ja) 2015-10-28
AU2007260185B2 (en) 2013-01-31
EP2032607B1 (en) 2014-01-22
JP2009539391A (ja) 2009-11-19
EP2032607A1 (en) 2009-03-11
DK3896090T3 (da) 2022-03-21
CA2655248C (en) 2016-02-09
PL2032607T3 (pl) 2014-06-30
EP3896090B1 (en) 2022-01-12
PL3896090T3 (pl) 2022-05-02
PL2032607T5 (pl) 2017-10-31
EP2032607B2 (en) 2017-02-22
ES2889920T3 (es) 2022-01-14
KR101641899B1 (ko) 2016-08-01
AU2007260185A1 (en) 2007-12-21

Similar Documents

Publication Publication Date Title
DK2256135T3 (da) Proteolytisk spaltbart fusionsprotein, der omfatter en blodkoagulationsfaktor
DK2032607T3 (da) Proteolytisk spalteligt fusionsprotein omfattende en blodkoaguleringsfaktor
ATE524493T1 (de) Exendin-fusionsproteine
DK2064334T3 (da) Aldehydtags, anvendelser deraf i site-specifik proteinmodificering
BRPI0716744A2 (pt) proteínas de fusão de albumina
DE602005024846D1 (de) Blutdialysator
FR2899308B1 (fr) Raccord rapide.
DE602006017452D1 (de) Kupplung mit winkelig ausgerichtetem Hohlraum
NO20082564L (no) Hepatosyttvekstfaktorintronfusjonsproteiner
DE602005017840D1 (de) Blutdruckmonitor
DK2426196T3 (da) Fremgangsmåder til fremstilling af modulære fusionsproteinekspressionsprodukter
FR2903164B1 (fr) Raccord rapide
DK1809660T3 (da) Thymus-specifikt protein
ES2569360T8 (es) Proteínas de fusión de ácaros
NO20053113D0 (no) Lasbar forsegling.
ITBO20040642A1 (it) Giunto vascolare
FR2891597B1 (fr) Joint homocinetique a rotule.
DE602006007833D1 (de) Blutdrucksenkende proteinhydrolysate
FR2919373B1 (fr) Raccord rapide perfectionne.
DK1857120T3 (da) Infusion til mastitis
FI20050800A0 (fi) Sormiliitos
ES1060498Y (es) Bastoncillo dental desechable.
ES1061431Y (es) Calzado perfeccionado
ATE548575T1 (de) Gleichlaufscheibegelenk
UA11631S (uk) Ланка з`єднувальна